Achieve Life Sciences Appoints Jeffrey Farrow and Reid Waldman, MD to Board of Directors
Globe Newswire (Tue, 2-Jun 8:30 AM ET)
Tarsus to Participate in Upcoming Investor Conferences
Globe Newswire (Thu, 28-May 4:30 PM ET)
Globe Newswire (Thu, 14-May 8:30 AM ET)
Tarsus Reports First Quarter 2026 Financial Results and Recent Business Achievements
Globe Newswire (Wed, 6-May 4:05 PM ET)
Tarsus to Report First Quarter 2026 Financial Results on Wednesday, May 6, 2026
Globe Newswire (Wed, 29-Apr 4:30 PM ET)
Globe Newswire (Tue, 31-Mar 8:30 AM ET)
Globe Newswire (Mon, 23-Mar 8:30 AM ET)
Tarsus Eyes $2 Billion Peak Sales on XDEMVY Momentum and Strategic Pipeline Expansion
Market Chameleon (Tue, 24-Feb 6:18 AM ET)
Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis. TP-04 for the potential treatment of ocular rosacea and TP-05 for potential Lyme disease prophylaxis and community malaria reduction.
Tarsus Pharmaceuticals trades on the NASDAQ stock market under the symbol TARS.
As of June 9, 2026, TARS stock price climbed to $61.55 with 588,477 million shares trading.
TARS has a beta of 0.16, meaning it tends to be less sensitive to market movements. TARS has a correlation of 0.00 to the broad based SPY ETF.
TARS has a market cap of $2.65 billion. This is considered a Mid Cap stock.
Last quarter Tarsus Pharmaceuticals reported $162 million in Revenue and -$.16 earnings per share. This beat revenue expectation by $12 million and exceeded earnings estimates by $.23.
In the last 3 years, TARS traded as high as $85.25 and as low as $12.57.
The top ETF exchange traded funds that TARS belongs to (by Net Assets): VTI, IWM, VXF, IWO, IBB.
TARS has outperformed the market in the last year with a price return of +40.1% while the SPY ETF gained +24.3%. However, in the short term, TARS had mixed performance relative to the market. It has underperformed in the last 3 months, returning -16.0% vs +9.9% return in SPY. But in the last 2 weeks, TARS shares have fared better than the market returning -1.1% compared to SPY -1.2%.
TARS support price is $57.75 and resistance is $61.54 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that TARS shares will trade within this expected range on the day.